Hims & Hers Expands GLP-1 Offering in Canada with Generic Semaglutide

Key Terms

generic semaglutide medical

Generic semaglutide is a widely available version of a medication originally developed to help control blood sugar levels and reduce appetite. It is used to treat conditions like type 2 diabetes and obesity, and its availability can influence the market for related drugs and healthcare costs. For investors, changes in its production or approval can impact pharmaceutical companies and the broader healthcare sector.

glp-1 medical

GLP-1 (glucagon-like peptide-1) is a natural hormone in the body that helps regulate blood sugar levels and appetite. Its significance to investors lies in its role as the basis for a class of medications that address conditions like type 2 diabetes and obesity, which are large and growing markets. Advances or investments in GLP-1-based treatments can signal opportunities in healthcare innovation and potentially impact pharmaceutical companies’ growth.

off-label medical

Off-label describes the use of an approved drug or medical device for a purpose, patient group, dose, or method that is not listed on its official regulatory label. Think of it like using a tool for a different job than the manufacturer describes: it can expand real-world demand but also raises questions about safety, reimbursement, and legal risk. Investors watch off-label use because it can boost sales quickly but may increase regulatory scrutiny, liability, or unpredictable revenue sustainability.

type 2 diabetes medical

Type 2 diabetes is a chronic condition where the body struggles to control blood sugar levels because it becomes less responsive to insulin, a hormone that helps regulate sugar in the blood. It matters to investors because it can lead to increased healthcare costs, affect workforce productivity, and influence the performance of companies in the healthcare and pharmaceutical sectors. Managing or preventing the condition has significant implications for public health and economic stability.

By introducing access to generic semaglutide in Canada, the company is meeting the needs of a dynamic market and continuing its international expansion efforts

SAN FRANCISCO--(BUSINESS WIRE)-- Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the availability of generic semaglutide through its platform in Canada. This is Hims & Hers’ first international generic GLP-1 offering, demonstrating the company’s ability to meet the unique needs of each global market it serves while continuing its international expansion efforts. Personalized treatment plans are available starting at $149 CAD/month, making effective, affordable GLP-1s accessible to Canadians for whom cost has long been a barrier to treatment.

By introducing access to generic semaglutide in Canada, the company is meeting the needs of a dynamic market and continuing its international expansion efforts

Nearly two-thirds of Canadian adults are overweight or living with obesity, but cost has remained a significant barrier to access the treatment they need. As the market becomes more dynamic and prices fall across the GLP-1 landscape, more eligible patients are now able to find the treatment that works best for their lifestyle and budget. This launch reflects Hims & Hers' ability to rapidly identify opportunities to help customers in global markets access safe, affordable care.

"Bringing generic semaglutide to Canada is a meaningful milestone, but it's also a signal of something larger: our conviction that the model we've built in the United States can and should serve customers around the world," said Mike Chi, Chief Operating Officer, Hims & Hers. "There are millions of people in markets around the world who are ready for more ways to find affordable, high-quality care. Our ability to enter a new market, build a locally credible program, deliver access to first-of-its-kind medical treatment, and generate real impact at scale is what sets us apart."

"Generics have always played a critical role in expanding access to medicines that change lives,” said Dr. Sandy Van, Obesity Medicine Specialist and Chief Medical Officer, Hims & Hers Canada. “Today marks a turning point: more choice, lower costs, and a genuine commitment to care built around the whole patient. Every Canadian deserves access to the treatment that's right for them, regardless of what they can afford."

Now through Hims & Hers, eligible customers in Canada will have access to personalised care plans that may include generic semaglutide or branded options, alongside unlimited and ongoing Care Team access and evidence-informed resources built around nutrition, movement, and sleep, all designed to support sustainable, lasting habits for long-term weight management. All Canadian customers are seen by Canadian providers who bring local clinical expertise and a deep understanding of the Canadian healthcare landscape.

Generic semaglutide is authorized for sale by Health Canada for the management of Type 2 diabetes. It may be prescribed off-label for weight management in a licensed healthcare provider's sole clinical judgment. Hims & Hers Canada Inc. does not currently offer access to treatment services for Type 2 diabetes.

About Hims & Hers Health, Inc.

Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That’s why we’re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the company provides access to personalized care designed for results. For more information, please visit www.hims.com and www.forhers.com.

Cautionary Note Regarding Forward-Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “believes,” “estimates,” “anticipates,” “expects,” “intends,” “plans,” “assume,” “may,” “will,” “likely,” “potential,” “projects,” “predicts,” “continue,” “goal,” “strategy,” “future,” “forecast,” “target,” “outlook,” “opportunity,” “project,” “confidence,” “foundation,” “groundwork,” or “should,” or, in each case, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations. Such statements include, but are not limited to, statements regarding Hims & Hers’ ability to expand internationally and serve customers around the globe, and any assumptions relating to the foregoing. These statements are based on management’s current expectations, but actual results may differ materially due to various factors.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, the forward-looking statements contained in this press release are based on our current expectations, assumptions and beliefs concerning future developments and their potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, uncertainties relating to our ability to successfully expand into new markets or specialties; our ability to launch new products or offerings on expected timelines or at all; expectations regarding market acceptance, user experience and customer retention; changes in healthcare, consumer protection or privacy laws; increased scrutiny from regulators; the impact of general economic, business, or financial conditions; and other factors described in the Risk Factors and other sections of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and other current and periodic reports we file from time to time with the Securities and Exchange Commission.

Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The forward-looking statements contained in this press release are made only as of May 20, 2026. We undertake no obligation (and expressly disclaim any obligation) to update or revise any forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from those made in or suggested by the forward-looking statements contained in this press release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260520249611/en/

Press Contact
Susan Cadrecha
press@forhims.com

Source: Hims & Hers